Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Biosig Technologies, Inc. (NASDAQ:BSGM - Free Report) by 966.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 266,435 shares of the company's stock after buying an additional 241,447 shares during the period. Cambridge Investment Research Advisors Inc. owned about 1.55% of Biosig Technologies worth $160,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Integrity Wealth Advisors Inc. purchased a new stake in Biosig Technologies during the fourth quarter worth $61,000. PFG Investments LLC boosted its position in Biosig Technologies by 43.5% during the first quarter. PFG Investments LLC now owns 158,286 shares of the company's stock worth $95,000 after purchasing an additional 48,000 shares in the last quarter. Geode Capital Management LLC purchased a new stake in Biosig Technologies during the fourth quarter worth $143,000. Millennium Management LLC purchased a new stake in Biosig Technologies during the fourth quarter worth $228,000. Finally, Legacy Investment Solutions LLC acquired a new stake in Biosig Technologies during the 4th quarter valued at $5,369,000. 7.16% of the stock is owned by hedge funds and other institutional investors.
Biosig Technologies Price Performance
Shares of BSGM stock traded up $0.18 during mid-day trading on Friday, hitting $4.93. 707,744 shares of the company's stock were exchanged, compared to its average volume of 439,551. Biosig Technologies, Inc. has a fifty-two week low of $0.23 and a fifty-two week high of $14.11. The stock has a 50-day simple moving average of $6.04 and a two-hundred day simple moving average of $2.68.
Biosig Technologies (NASDAQ:BSGM - Get Free Report) last posted its quarterly earnings data on Monday, May 19th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.09). Equities research analysts expect that Biosig Technologies, Inc. will post -0.88 EPS for the current year.
Wall Street Analysts Forecast Growth
Separately, Ascendiant Capital Markets increased their target price on Biosig Technologies from $2.50 to $10.00 and gave the company a "buy" rating in a report on Friday, June 6th.
View Our Latest Stock Analysis on BSGM
Biosig Technologies Profile
(
Free Report)
BioSig Technologies, Inc, together with its subsidiaries, a medical device company, engages in development and commercialization of advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias in the United States. It offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures.
Further Reading
Before you consider Biosig Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biosig Technologies wasn't on the list.
While Biosig Technologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access Sale